74901-71-6

Usage

Uses

Used in Pharmaceutical Synthesis:
2,4-dichloro-5,7-dihydrothieno[3,4-d]pyriMidine is utilized as a key building block in the synthesis of various drug molecules. Its unique structure and functional groups contribute to the development of new pharmaceuticals with potential therapeutic benefits.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2,4-dichloro-5,7-dihydrothieno[3,4-d]pyriMidine is studied for its potential biological activities. Researchers are exploring its interactions with biological targets and evaluating its efficacy in treating specific diseases or conditions.
Used in Drug Development:
2,4-dichloro-5,7-dihydrothieno[3,4-d]pyriMidine's potential applications in drug development make it a valuable asset in the pharmaceutical industry. By incorporating 2,4-dichloro-5,7-dihydrothieno[3,4-d]pyriMidine into drug molecules, scientists aim to create novel therapeutic agents with improved efficacy, selectivity, and safety profiles.

Upstream product

• 5719-34-6 5,7-dihydrothieno[3,4-d]pyrimidine-2,4-diol 
• 2689-68-1 methyl 4-oxotetrahydrothiophene-3-carboxylate 
• 7400-45-5 dimethyl-3-thiaadipate 
• 5719-34-6 5H,7H-2-dihydrothieno<3,4-d>pyrimidine-2,4-dione 
• 5719-20-0 5H,7H-2-ethylthiodihydrothieno<3,4-d>pyrimidin-4-one 

Downstream Products

• 1429638-92-5 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)urea 
• 1429638-93-6 (S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-2-yl)phenyl)urea 

Relevant academic research and scientific papers

TREATMENT OF INFECTIOUS DISEASES WITH GLUCOSE UPTAKE INHIBITORS

Provided are methods of treating infectious diseases in mammals comprising administering a compound that inhibits glucose uptake. Particular infectious diseases that may be treated include malaria, leishmaniasis, African trypanosomiasis, tuberculosis, HIV, HCMV or herpes virus. In a first aspect, the invention features a method of treating infectious diseases in a mammal, comprising administering to a mammalian subject in need thereof a therapeutically effective amount of a compound or prodrug thereof, or pharmaceutically acceptable salt or ester of said compound or prodrug, wherein the compound is an inhibitor of glucose uptake.

GLUCOSE UPTAKE INHIBITORS

Provided hererin are compounds that modulate glucose uptake activityand are useful for treating cancer, autoimmune diseases, inflammation, infectious diseases, and metabolic diseases. In certain embodiments, the compounds modulate glucose uptake activity by modulating cellular components, including, but not limited to those related to glycolysis and known transporters/co-transporters of glucose such as GLUT1 and other GLUT family members/alternative hexose transporters. In certain embodiments, the compounds have the structure of formula I: Formula (I) wherein the variables have the values disclosed herein.

MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS

The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments